CorMedix Inc Operating Expenses 2011-2024 | CRMD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

CorMedix Inc operating expenses from 2011 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

CorMedix Inc operating expenses from 2011 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$158B
Bristol Myers Squibb (BMY)	$119.2B
Vertex Pharmaceuticals (VRTX)	$118.9B
Gilead Sciences (GILD)	$112.8B
CSL (CSLLY)	$88.8B
Regeneron Pharmaceuticals (REGN)	$82.4B
GSK (GSK)	$70.8B
Argenex SE (ARGX)	$36.6B
Alnylam Pharmaceuticals (ALNY)	$32.4B
BioNTech SE (BNTX)	$29B
Biogen (BIIB)	$23.1B
Illumina (ILMN)	$22.8B
BeiGene (BGNE)	$18.5B
Moderna (MRNA)	$16.8B
Incyte (INCY)	$14.2B
Genmab (GMAB)	$13.8B
Insmed (INSM)	$13.3B
BioMarin Pharmaceutical (BMRN)	$12.4B
Bio-Techne Corp (TECH)	$11.8B
Vaxcyte (PCVX)	$11.4B
Sarepta Therapeutics (SRPT)	$11B
Exelixis (EXEL)	$10.4B
Exact Sciences (EXAS)	$10.2B
QIAGEN (QGEN)	$9.9B
Revolution Medicines (RVMD)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$9.1B
Intra-Cellular Therapies (ITCI)	$9B
Repligen (RGEN)	$8.2B
Ascendis Pharma (ASND)	$7.9B